Do Analysts Think Xeris Biopharma Holdings Inc (XERS) Is Still Worth Buying In 2024?

Xeris Biopharma Holdings Inc (NASDAQ:XERS) does about 1.99M shares in volume on a normal day but saw 1773585 shares change hands in Monday trading. The company now has a market cap of 259.83M USD. Its current market price is $1.85, marking a decrease of -3.14% compared to the previous close of $1.91. The 52 week high reached by this stock is $3.26 whilst the lowest price level in 52 weeks is $1.46.

Xeris Biopharma Holdings Inc (XERS) has a 20-day trading average at $2.0660 and the current price is -43.25% off the 52-week high compared with 26.71% distance from its 52-week low. The 50-day simple moving average of the closing price is $2.4937 and its 200-day simple moving average is $2.2278. If we look at the stock’s price movements over the week, volatility stands at 5.49%, which decreases to 5.21% over 1 month. It is also key to look at other market indicators of price movement for the stock, where we see that the relative strength index (RSI) is at 29.57 to suggest the stock is oversold.

The consensus objective for the share price is $4.75, suggesting that the stock has a potential upside of 61.05% over the period.

The company shares received a number of brokerage firm price updates over the past month, with the latest being on March 28, 2024 when Oppenheimer initiated the stock to “Outperform” and issued a price target of $5. Jefferies initiated its price target at $4.

Xeris Biopharma Holdings Inc (XERS) stock is down -8.42% over the week and -13.15% over the past month. Its price is -21.28% year-to-date and -15.14% over the past year.

To reach the target analysts have set, the stock logically needs to grow 61.05 percent from here.

The company has a return on investment of -28.44% and return on equity of -324.20%. The beta has a value of 1.64. Price to sales ratio is 1.59.